Thursday, Nov 10, 2005

Biogen Idec and Genentech Announce November 16th Webcast Discussion of Rituxan Data Presented at ACR

South San Francisco, Calif. -- November 10, 2005 --

Genentech, Inc. (NYSE: DNA) and Biogen Idec Inc. (Nasdaq: BIIB) invite investors, the media and the general public to listen to an audio webcast discussing data for Rituxan® (Rituximab) in rheumatoid arthritis (RA) to be presented at the 2005 American College of Rheumatology (ACR) Annual Scientific Meeting in San Diego.

The webcast will begin at 2:00 p.m. Pacific Time on November 16, 2005 and will be archived until 5:00 p.m. Pacific Time on November 23, 2005. The webcast will be available on both companies' websites at http://www.gene.com and http://www.biogenidec.com. An audio telephone replay will also be available beginning at 5:00 p.m. Pacific Time on November 16, 2005 through 5:00 p.m. Pacific Time on November 23, 2005. Access numbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291 (international); Conference ID number is 1749709.

About Genentech
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from, or are based on, Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States, and receives royalties or other income from companies that are licensed to market its products outside of the United States. The company has headquarters in South San Francisco, Calif., and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.

About Biogen Idec
Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.

###